KRAS and non-small cell lung carcinoma: Meraz and colleagues [292] utilized nanovesicles to deliver tumor suppressor gene TUSC2 and found improvement in the efficacy of carboplatin plus pembrolizumab in KRAS/TP53 co-mutated NSCLC, mediated by immune microenvironment regulation.